Sensus Healthcare, Inc. (NASDAQ:SRTS) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET
Company Participants
Kim Sutton Golodetz - LHA, IR
Joe Sardano - Chairman & CEO
Michael Sardano - President & General Counsel
Javier Rampolla - CFO
Conference Call Participants
Boobalan Pachaiyappan - H.C. Wainwright
Alex Nowak - Craig-Hallum Capital Group
Ben Haynor - Alliance Global Partners
Operator
Good afternoon and welcome to the Sensus Healthcare Third Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions]. After today's presentation, there will be an opportunity to ask questions. [Operator Instructions]. Please note this event is being recorded.
I would now like to turn the conference over to Kim Sutton Golodetz, LHA Investor Relations. Please go ahead.
Kim Sutton Golodetz
Thank you. This is Kim Golodetz with LHA. Thank you all for participating in today's call. Joining me from Sensus Healthcare are Joe Sardano, Chairman and Chief Executive Officer; Michael Sardano, President and General Counsel; and Javier Rampolla, Chief Financial Officer.
As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meaning of federal securities law. All statements other than historical facts that address activities Sensus Healthcare assumes, plans, expects, believes, intends or anticipates and other similar expressions will, should or may occur in the future are forward-looking statements.
The forward-looking statements are management's beliefs based on currently available information as of the date of this conference call, November 9, 2023. Sensus Healthcare undertakes no obligation to revise or update any forward-looking statements except as required by law. All forward-looking statements are subject to risks and uncertainties as described in the company's Forms 10-K and 10-Q.
During today's call, references will be made to certain non-GAAP financial measures. Sensus believes these measures provide useful information for investors, yet they should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in today's financial results press release.
With that said, I'd like to turn the call over to Joe Sardano. Joe?
Joe Sardano
Thank you, Kim. Good afternoon, everyone.
Our third quarter financial results reflected typical summer seasonality and macroeconomic conditions with economic challenges continuing to affect many dermatologists. During Q3, we shipped 11 systems, including three SRT systems outside the U.S. and five SRT-100 Visions to a very large customer. Total unit sales now stand at almost 720 units, and we expect the seasonally strong fourth quarter to help us advance towards our yearly and long-term goal.